• Fef Rukminingsih Doctoral Student at Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Tri Murti Andayani Pharmacology and Clinical Pharmacy Department, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Fita Rahmawati Pharmacology and Clinical Pharmacy Department, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, Indonesia
  • Kartika Widayati Internal Medicine Department, Faculty of Medicine, Universitas Gadjah Mada, Yogyakarta, Indonesia


Objective: The management of early breast cancer (EBC) is performed with a series of treatments consisting of surgery and systemic therapy, along with long-term endocrine therapy for hormone responsive. The treatment generates a high illness effect that will affect the life quality of EBC patients. The objective of this study was to measure EBC patients’ quality of life after undergoing the treatment.

Methods: A cross-sectional study was conducted by interviewing EBC patients using EQ-5D-5L instrument at private hospitals in Yogyakarta and Semarang, Indonesia. The EBC patients were women aged 18-60 y who had undergone surgery in 2010-2013 and received endocrine therapy.

Results: Of the 71 patients identified, 45 patients were in disease-free survival (DFS) state, 8 patients were in locoregional recurrence (LR), and 18 patients were in metastasis (M) state. Mobility and self-care problems occurred in patients who had metastasis (4.23%). The problem of usual activities occured in patients who had recurrence (22.54%). Most of the patients (84.51%) had pain problem, and all patients had an anxiety problem. The mean utility score (SD) in DFS patients was 0.841 (0.052), in LR patients was 0.758 (0.092), and in patients who had metastasis was 0.653 (0.104). The mean scores of EQ-5D VAS (SD) for EBC patients in DFS, LR and M health state were 86.56 (6.29), 81.88 (5.30), and 69.17 (5.75), respectively.

Conclusion: The health states of EBC significantly affect HRQOL of patients. Efforts should be made to improve the quality of life of EBC patients especially in terms of pain and anxiety reduction.

Keywords: Early breast cancer, EQ-5D-5L, HRQOL, Utility


Download data is not yet available.


1. Kementerian Kesehatan Republik Indonesia. Stop kanker. Jakarta: Pusat data dan informasi Kementerian Kesehatan Republik Indonesia; 2015.
2. Mulyani S. Menopause: end of the menstrual cycle. In: Women in the Middle Ages. Yogyakarta: Nuha Medika; 2013.
3. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow up. Annal Oncol 2015;26:8-30.
4. Suyatno. Breast Cancer. Bedah onkologi diagnostik dan terapi. Jakarta: Sagung Seto; 2010.
5. Palu MB, Nurdin AA. Lost potency based on the health-related quality of life on breast cancer in Makasar South Sulawesi. Medula 2014;2:97-107.
6. Sanigaram V, Lingampally S, Boyana A, Vurumadla S. A prospective study on clinical evaluation, treatment pattern and adverse effects of anticancer drugs in various gynaecological cancer patients. Asian J Pharm Clin Res 2015;8:125-31.
7. Teckle P, Peacock S, McTaggart Cowan H, Hoek KVD, Chia S, Melosky B, et al. The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Quality Life Outcomes 2011;9:106.
8. Longworth L, Yang Y, Young T, Mulhern B, Hernandez AM, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modeling, and survey. Health Technol Assess 2014;18:1-224.
9. Devlin NJ, Krabbe PF. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ 2013;14 Suppl 1:S1-3.
10. Oemar M, Janssen B. User guide: basic information on how to use EQ-5D-5L instrument. EuroQol Group; 2013.
11. Oemar M, Oppe M. User guide: basic information on how to use EQ-5D-3L instrument. Eur Qol Group; 2013.
12. Drummond F, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press; 2005.
13. Euro Qol Group. EQ-5D-5L. Available from: http://www. [Last accessed on 12 Jun 2016].
14. Purba FD, Hunfeld JAM, Iskandarsyah A, Fitriana TS, Sadarjoen SS, Passchier J, et al. The indonesian EQ-5D-5L value set. Pharmacol Economics 2017;35:1153-65.
15. Matalqah LM, Radaideh KM, Yusoff ZM, Awaisu A. Health-related quality of life using EQ-5D among breast cancer survivors in comparison with age-matched peers from the general population in the state of Penang, Malaysia. J Public Health 2011;19:475-80.
16. Marcus DA. Epidemiology of cancer pain. Curr Pain Headache Rep 2011;15:231-4.
17. Galloway SK, Baker M, Giglio P, Chin S, Madan A, Malcolm R, et al. Depression and anxiety symptoms relate to distinct components of pain experience among patients with breast cancer. Pain Res Treat 2012;851276. Doi: 10.1155/2012/ 851276.
18. Balaji O, Bairy KL, Veena N. Management of depression in terminally ill patients–a critical review. Asian J Pharm Clin Res 2017;10:31-6.
19. Traeger L, Greer JA, Fernandez Robles C, Temel JS, Pirl WF. Evidence-based treatment of anxiety in patients with cancer. J Clin Oncol 2012;30:1197-205.
97 Views | 187 Downloads
How to Cite
Rukminingsih, F., T. Andayani, F. Rahmawati, and K. Widayati. “HEALTH-RELATED QUALITY OF LIFE IN EARLY BREAST CANCER PATIENTS WITH HORMONE RESPONSIVE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 10, no. 12, Dec. 2018, pp. 47-49, doi:10.22159/ijpps.2018v10i12.29648.
Original Article(s)